CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
about
Harnessing the immune system to improve cancer therapyOncolytic viruses as immunotherapy: progress and remaining challengesTo Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesThe Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor BedsTrial Watch-Oncolytic viruses and cancer therapyFOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsTargeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.CAR T-cell immunotherapy: The path from the by-road to the freeway?Active Immunotherapy of Cancer.CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection.Oncolytic virotherapy for urological cancers.Oncolytic Immunotherapy for Treatment of Cancer.Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients.Immuno-oncology combinations: raising the tail of the survival curve.Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.Oncolytic Virotherapy and the Tumor Microenvironment.Cancer stem cell and its niche in malignant progression of oral potentially malignant disorders.Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.S100B Mediates Stemness of Ovarian Cancer Stem-Like Cells Through Inhibiting p53.miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers.The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor MicroenvironmentModulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic MiceThree-dimensional tumor cell cultures employed in virotherapy researchCancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu
P2860
Q26738698-508334E6-B6C1-4577-8BAB-164DF812905DQ26745942-2B136C93-0160-482F-9420-5BBFEE8B69D1Q26767212-FDC7C746-28E1-498A-BC8C-7447FEDC37CFQ26799120-C84E62C1-19C0-4B95-80DA-AC4AEF72BEE2Q28072347-E3D1C98C-233F-4BCB-BB72-956099EF3072Q33651605-F5D3F36F-FD68-4230-AC70-C22C52DA0864Q35793791-D734C512-82EE-4DFD-BA71-3DE49726A02EQ36964853-C95E90FD-F109-450C-9FC1-8AB377715FE5Q37502464-5FD19A4B-039E-428F-830E-5AEAFB7C1E02Q38472331-0D89B04D-AA8B-493F-8E62-B4305B679303Q38632105-69BCD317-05B4-4E3F-9B19-D99DAF014A9DQ38635419-A7EA8059-0C77-45E9-9E88-1B2EC73D2C36Q38780546-9E27EFBA-72DE-4DE2-B36A-A0C794DCF648Q38842126-88B35107-68EA-4566-9FCC-EF73C75B72CBQ38848223-20CDAA14-079E-4845-9F78-D71669461F2CQ38924557-2BB0CB96-5649-4251-9637-74ECBCDFD6CFQ39130451-5CA2FBE2-FFDD-4DDF-AB26-E287BAAC5F13Q41098451-C73AB2CF-0A1F-4C1A-B42F-1B940537AE67Q42421273-8B7D96B5-3C8A-43CD-8F8E-EC339B2EAE81Q42516478-1D5CE057-1ABA-4B71-86C8-D0EEA5319A07Q46047154-A9997B6D-20A0-4674-B1F6-577AD6F33E5FQ46246670-5A97F8F6-49DA-4864-A008-99AEBB9C2189Q47560690-77AEFB0A-A281-4C69-BA87-E30487E23E58Q49965709-D31C9CC7-6FE4-4BCC-9AB9-F59CD7B4262CQ50580618-16230501-5EFC-4D2C-BCE5-FC118BA7BD9DQ51584798-E67D9297-5345-47BD-9846-8935F7968F0DQ54975654-198D44C2-01A4-4159-9DF6-E202562EE13BQ57492022-55337EBE-B7DB-4987-8D3E-68F094816937Q58701885-90E62B47-FF10-4283-B348-738AA949D15FQ58763072-5232701C-9126-415B-9102-AFDE0667D337Q58781616-45905B54-786C-4499-915D-3BBADEF12893
P2860
CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@ast
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@en
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@nl
type
label
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@ast
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@en
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@nl
prefLabel
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@ast
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@en
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@nl
P2093
P2860
P921
P356
P1476
CXCL12/CXCR4 blockade by oncol ...... eting cancer-initiating cells.
@en
P2093
A J Robert McGray
Danuta Kozbor
Hanna Rokita
Kunle O Odunsi
Marcin P Komorowski
Margaret Gil
Mateusz Opyrchal
Mukund Seshadri
P2860
P304
P356
10.4049/JIMMUNOL.1400201
P407
P577
2014-10-15T00:00:00Z